Captor Therapeutics Spolka Akcyjna
CTX.WA · WSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | PLN 16 | PLN 13 | PLN 9 | PLN 4 |
| % Growth | 19.9% | 44.1% | 129.8% | – |
| Cost of Goods Sold | PLN 9 | PLN 6 | PLN 2 | PLN 1 |
| Gross Profit | PLN 6 | PLN 7 | PLN 7 | PLN 3 |
| % Margin | 40.6% | 52.3% | 77.2% | 81.4% |
| R&D Expenses | PLN 35 | PLN 65 | PLN 44 | PLN 23 |
| G&A Expenses | PLN 4 | PLN 16 | PLN 20 | PLN 20 |
| SG&A Expenses | PLN 17 | PLN 22 | PLN 20 | PLN 20 |
| Sales & Mktg Exp. | PLN 12 | PLN 6 | PLN 0 | PLN 0 |
| Other Operating Expenses | PLN 0 | -PLN 7 | -PLN 18 | -PLN 8 |
| Operating Expenses | PLN 51 | PLN 80 | PLN 45 | PLN 35 |
| Operating Income | -PLN 45 | -PLN 73 | -PLN 38 | -PLN 32 |
| % Margin | -282.8% | -553.1% | -418.9% | -795.5% |
| Other Income/Exp. Net | PLN 1 | PLN 2 | PLN 2 | -PLN 1 |
| Pre-Tax Income | -PLN 38 | -PLN 71 | -PLN 36 | -PLN 33 |
| Tax Expense | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| Net Income | -PLN 38 | -PLN 71 | -PLN 36 | -PLN 33 |
| % Margin | -242.8% | -534.7% | -391.9% | -817.2% |
| EPS | -8.25 | -15.19 | -8.61 | -7.89 |
| % Growth | 45.7% | -76.4% | -9.1% | – |
| EPS Diluted | -8.25 | -15.19 | -8.61 | -7.89 |
| Weighted Avg Shares Out | 5 | 5 | 4 | 4 |
| Weighted Avg Shares Out Dil | 5 | 5 | 4 | 4 |
| Supplemental Information | – | – | – | – |
| Interest Income | PLN 1 | PLN 3 | PLN 3 | PLN 0 |
| Interest Expense | PLN 0 | PLN 0 | PLN 1 | PLN 0 |
| Depreciation & Amortization | PLN 5 | PLN 5 | PLN 7 | PLN 7 |
| EBITDA | -PLN 33 | -PLN 65 | -PLN 28 | -PLN 24 |
| % Margin | -208.1% | -490.6% | -308.2% | -612.4% |